Mastectomy or lumpectomy — how the choice gets made

It is one of the most common questions in a breast cancer consultation: mastectomy or lumpectomy (also called wide local excision)? The answer for any individual patient depends on a small number of specific factors, but the question itself is often phrased as if mastectomy were the “safer” choice, or as if lumpectomy were the “less serious” choice. Neither framing is right.

This piece explains how the decision actually gets made: what the operations are, what they preserve, what the trade-offs are, and how a thoughtful patient can think about it.

The two operations, briefly

• Lumpectomy, also called wide local excision or breast-conserving surgery, removes the cancer with a rim of healthy tissue around it, preserving the rest of the breast. Almost always followed by radiotherapy to the remaining breast tissue.
• Mastectomy removes the whole breast. May or may not include immediate reconstruction. Often does not need radiotherapy afterwards.

The two operations have equivalent long-term survival outcomes for the cancers they are used to treat. This has been one of the most consistent findings in breast cancer research over the past 40 years: lumpectomy plus radiotherapy and mastectomy alone produce the same survival in patients for whom both are oncologically appropriate. UK early breast cancer care follows NICE guideline NG101: when breast-conserving surgery plus radiotherapy is suitable, survival is comparable to mastectomy.

What differs is everything else: the recovery, the breast appearance, whether radiotherapy is given, the long-term experience of having (or not having) breast tissue.

What decides between them

The choice depends on a small number of specific factors. The first three are clinical; the rest are personal.

1. Can the cancer be removed with a clear margin while leaving an acceptable cosmetic result?

The fundamental question. If a lumpectomy can remove the cancer with a clear rim of healthy tissue and leave a breast that the patient is happy with, lumpectomy is on the table. If it cannot, because the cancer is too large relative to the breast, or because the position would distort the breast significantly, mastectomy is on the table.

For some patients in the middle, oncoplastic surgery, particularly therapeutic mammoplasty, where the breast is reshaped using cosmetic-surgery techniques while the cancer is removed, opens up a third option that lets a larger cancer be treated with breast-conserving surgery.

2. Is the cancer in one place, or in multiple separate areas?

• One cancer, one breast: typically suitable for lumpectomy.
• Multiple separate cancers in the same breast (multifocal or multicentric): sometimes still suitable for lumpectomy, but more often warranting mastectomy because clearing several areas through one operation is difficult.

This is one of the questions breast MRI sometimes answers when the standard imaging is not clear, particularly for invasive lobular carcinoma, which has a higher rate of multifocal presentation.

3. Can the patient have radiotherapy?

Lumpectomy is almost always followed by radiotherapy to the remaining breast tissue, and the equivalence-of-outcome between lumpectomy and mastectomy depends on the radiotherapy being given. Patients who cannot have radiotherapy, because they have had previous radiotherapy to the same area, because of specific medical conditions, or for other reasons, usually have mastectomy instead.

4. The patient’s preference

Beyond the clinical factors, what the patient wants matters. This is where the conversation often becomes harder, because patients sometimes feel they should choose what is “safer” rather than what they want, and end up choosing the operation they assume to be safer (often, mistakenly, mastectomy).

The reality:

• Survival is the same for the cancers where both operations are appropriate.
• Recurrence rates are slightly higher in the conserved breast after lumpectomy than after mastectomy, but most recurrences in the conserved breast are caught early on surveillance and successfully treated. Long-term cancer-specific survival remains equivalent.
• The risk of a new, separate cancer in either breast in the future is similar after both operations. The patient is not “protected” by mastectomy from a future contralateral cancer.

For patients who genuinely prefer mastectomy (for psychological reasons, for the avoidance of radiotherapy, for the simplicity of one operation rather than the surgery-plus-radiotherapy package), that preference is a legitimate input into the decision and should be respected.

For patients who would prefer to keep the breast if it is safe to do so, lumpectomy is a reasonable choice that does not compromise their long-term outlook.

What people often think. And what’s actually true

Some common framings worth pushing back on:

“Mastectomy is the safer choice.”

For the cancers where both are appropriate, this is not true. Long-term survival is the same. The “safety” of mastectomy is largely psychological (the feeling that “more has been removed”) rather than a real difference in outcome. For an unsuitable cancer (large, multifocal, or one that cannot have radiotherapy), mastectomy may indeed be necessary, but that is a clinical-suitability question, not a safety question.

“Lumpectomy is for less serious cancers.”

Also not true. Lumpectomy is for cancers that are the right shape and size for breast-conserving surgery, regardless of how aggressive the cancer’s biology is. A small but high-grade cancer can be treated with lumpectomy plus radiotherapy plus appropriate adjuvant treatment; a large but low-grade cancer might need mastectomy on size grounds alone.

“I’ll need radiotherapy either way, so I might as well have lumpectomy.”

Not quite. Radiotherapy is almost always given after lumpectomy but often not given after mastectomy. Most patients who have mastectomy do not need radiotherapy. (Some do, particularly with significant lymph node involvement.) For patients who strongly want to avoid radiotherapy, mastectomy can be a reasonable choice on that ground.

“Mastectomy means I don’t need to worry about that breast again.”

Mastectomy substantially reduces the chance of further cancer in that breast, but does not reduce it to zero. A small amount of breast tissue remains in the chest wall after any mastectomy, and rare recurrences can occur. Surveillance after mastectomy (including the chest wall) continues for years.

What about reconstruction?

If mastectomy is the right operation, the next decision is reconstruction. The three main options:

• Implant-based reconstruction: silicone implant placed at the time of mastectomy. Shorter operation, faster recovery; implants typically need revision over time.
• Autologous reconstruction: using the patient’s own tissue, most commonly a DIEP flap from the lower abdomen. Longer operation and recovery; the result feels and ages more like a natural breast and usually does not need revision.
• Aesthetic flat closure: a deliberate surgical choice not to reconstruct, with care taken to leave a smooth, flat chest wall.

For a longer piece on this decision, see choosing reconstruction.

The reconstruction conversation usually happens at the same consultation as the mastectomy decision, so that you can choose with the full picture in front of you: what surgery, with or without reconstruction, with which type of reconstruction.

How the conversation usually goes at consultation

A good consultation about this decision, at NHS or private practice, usually includes:

• The cancer’s specifics: size, position, type, biology.
• What lumpectomy would look like in your specific case: what scar, what cosmetic result, what radiotherapy course.
• What mastectomy would look like: type (skin-sparing, nipple-sparing, simple), with or without reconstruction.
• The chance of needing a second operation: particularly the chance of needing a re-excision after lumpectomy if the margin comes back involved (typically 10–25%).
• Your priorities: what you want most from the recovery, what you want from the cosmetic outcome, what feels right.

Most patients leave the consultation with a clearer view of what they want, but not with a final decision, and that is fine. A second appointment to think things through is normal and recommended.

A small number of patients are clear at the first consultation; most take a second appointment, sometimes a third. There is no clinical urgency to make the decision in a single conversation. Cancer treatment that begins three weeks after diagnosis has the same outcome as cancer treatment that begins one week after diagnosis.

Questions worth asking

To bring to consultation:

• In my specific case, are both operations clinically suitable?
• If both are suitable, what is the cosmetic difference I should expect from each?
• What is the chance of needing a re-excision after lumpectomy in my case?
• What radiotherapy would follow lumpectomy: duration, side effects, scheduling?
• For mastectomy, what reconstruction options do I have, and what does each involve?
• What does the multidisciplinary team think: is there a recommendation, or are both reasonable?

If you are seeing more than one surgeon for second opinions, take the same questions to each. The answers should be broadly consistent across UK specialist practice; where they are not, that is itself useful information.

A note on time

Modern breast cancer treatment has improved substantially over the past two decades, particularly for cancers that respond to hormone therapy, HER2-targeted therapy, and the newer agents for triple-negative disease. For most patients, the decision about surgery is not a snap one. There is time to think, to ask, to seek a second opinion, and to weigh up the trade-offs.

A patient who chooses lumpectomy and later needs to convert to mastectomy (for an involved margin or recurrence) loses very little. A patient who chooses mastectomy and later regrets it cannot easily go back. Where both operations are appropriate, the less drastic one is often the right starting choice, with mastectomy held in reserve as a fallback if needed.

For patients who want time to consider, the consultation pathway at this practice, with longer first appointments and the option of second appointments before any decision, is designed for this.

What to do next

For a private consultation, contact Sarah or Nadiya, Dr Tsang-Wright’s PAs, at [email protected] or 07785 274 744. For NHS care, your GP can refer you on the standard pathway.

If you have an existing diagnosis and want a second opinion on a treatment plan from another centre, the practice welcomes those referrals. Bring the histology, imaging, and MDT outcome letter from the original centre.